Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended‐Release Niacin in Hyperlipidemic Patients
Authors:
Open Access
- 22 August 2013
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 2 (4) , e000037
Abstract
Background: Combination therapy with ezetimibe/simvastatin (E/S) and extended‐release niacin (N) has been reported to be safe and efficacious in concomitantly reducing low‐density lipoprotein cholesterol and increasing high‐density lipoprotein cholesterol in hyperlipidemic patients at high risk for atherosclerotic cardiovascular events. This analysis evaluated the effect of E/S coadministered with N on low‐density lipoprotein particle number ( LDL ‐P) and high‐density lipoprotein particle number ( HDL ‐P) as assessed by nuclear magnetic resonance ( NMR ) spectroscopy in patients with type II a or II b hyperlipidemia. Methods and Results: This was an analysis of a previously reported 24‐week randomized, double‐blind study in type II a/ II b hyperlipidemic patients randomized to treatment with E/S (10/20 mg/day)+N (titrated to 2 g/day) or N (titrated to 2 g/day) or E/S (10/20 mg/day). Samples from a subset of patients (577 of 1220) were available for post hoc analysis of LDL ‐P and HDL ‐P by NMR spectroscopy. Increases in HDL ‐P (+16.2%) and decreases in LDL ‐P (−47.7%) were significantly greater with E/S+N compared with N (+9.8% for HDL ‐P and −21.5% for LDL ‐P) and E/S (+12.8% for HDL ‐P and −36.8% for LDL ‐P). In tertile analyses, those with the lowest baseline HDL ‐P had the greatest percent increase in HDL ‐P (N, 18.4/7.9/2.1; E/S, 19.3/12.2/5.3; and E/S+N, 26.9/13.8/6.9; all P P <0.001). Conclusions: These results suggest that E/S+N improves lipoprotein particle number, consistent with its lipid‐modifying benefits in type II a or II b hyperlipidemia patients and may exert the greatest effect in those with high LDL ‐P and low HDL ‐P at baseline. Clinical Trial Registration: URL: Clinicaltrials.gov Identifier: NCT00271817Keywords
This publication has 47 references indexed in Scilit:
- High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary EventsJACC, 2012
- Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapyVascular Health and Risk Management, 2012
- Clinical implications of discordance between low-density lipoprotein cholesterol and particle numberJournal of Clinical Lipidology, 2011
- Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapyVascular Health and Risk Management, 2010
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?Lipids in Health and Disease, 2010
- Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targetsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2010
- Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic SyndromeDiabetes Care, 2009
- Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidenceJournal of Clinical Lipidology, 2007
- Value of Low-Density Lipoprotein Particle Number and Size as Predictors of Coronary Artery Disease in Apparently Healthy Men and WomenJACC, 2007